Defining optimized properties of modified mRNA to enhance virus-and DNA-independent protein expression in adult stem cells and fibroblasts

Cellular Physiology and Biochemistry

Volumn 35, Issue 4, 2015, Pages 1360-1371

  Hausburg, Frauke ^a   Na, Silke ^a   Voronina, Natalia ^a   Skorska, Anna ^a   Müller, Paula ^a   Steinhoff, Gustav ^a   David, Robert ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Adult stem cells; DNA free; Fibroblasts; Modified mRNA; Non viral; Reprogramming; Trans differentiation

Indexed keywords

CYTIDINE TRIPHOSPHATE; ENHANCED GREEN FLUORESCENT PROTEIN; MESSENGER RNA; MYOD PROTEIN; 5-METHYLCYTIDINE; CYTIDINE; DNA; GREEN FLUORESCENT PROTEIN; PSEUDOURIDINE;

ADULT; ADULT STEM CELL; ANIMAL CELL; ARTICLE; CELL FATE; CELL PROLIFERATION; CELL VIABILITY; CHEMICAL MODIFICATION; CONTROLLED STUDY; DNA TEMPLATE; FIBROBLAST; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MESENCHYMAL STEM CELL; MOUSE; MYOBLAST; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; PROCESS OPTIMIZATION; PROTEIN EXPRESSION; RNA SYNTHESIS; ANALOGS AND DERIVATIVES; ANIMAL; CELL CULTURE; CHEMISTRY; CHLOROCEBUS AETHIOPS; COS 1 CELL LINE; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENE THERAPY; GENETICS; MESENCHYMAL STROMA CELL; METABOLISM; VIRUS;

ADULT STEM CELLS; ANIMALS; CELLS, CULTURED; CELLULAR REPROGRAMMING; CERCOPITHECUS AETHIOPS; COS CELLS; CYTIDINE; DNA; FIBROBLASTS; GENE EXPRESSION REGULATION; GENETIC THERAPY; GREEN FLUORESCENT PROTEINS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; MYOD PROTEIN; PSEUDOURIDINE; RNA, MESSENGER; TRANSFECTION; VIRUSES;

EID: 84924176438     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000373957     Document Type: Article

References (36)

1. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S: Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131:861-72.
2. Zhou Q, Brown J, Kanarek A, Rajagopal J, Melton DA: In vivo reprogramming of adult pancreatic exocrine cells to beta-cells. Nature 2008;455:627-32.
3. Vierbuchen T, Wernig M: Direct lineage conversions: unnatural but useful? Nat. Biotechnol. 2011;29:892-907.
4. Szabo E, Rampalli S, Risuefio RM, Schnerch A, Mitchell R, Fiebig-Comyn A, Levadoux-Martin M, Bhatia M: Direct conversion of human fibroblasts to multilineage blood progenitors. Nature 2010;468:521-6.
5. Ieda M, Fu J, Delgado-Olguin P, Vedantham V, Hayashi Y, Bruneau BG, Srivastava D: Direct reprogramming of fibroblasts into functional cardiomyocytes by defined factors. Cell 2010;142:375-86.
6. Qian L, Huang Y, Spencer CI, Foley A, Vedantham V, Liu L, Conway S J, Fu J, Srivastava D: In vivo reprogramming of murine cardiac fibroblasts into induced cardiomyocytes. Nature 2012;485:593-8.
7. David R, Joos TO, Dreyer C: Anteroposterior patterning and organogenesis of Xenopus laevis require a correct dose of germ cell nuclear factor (xGCNF). Mechanisms of Development 1998;79:137-52.
8. Kriegmair, Maximilian C M, Frenz S, Dusl M, Franz W, David R, Rupp, Ralph AW: Cardiac differentiation in Xenopus is initiated by mespa. Cardiovasc. Res. 2013;97:454-63.
9. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL: Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
10. Gilboa E, Vieweg J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 2004;199:251-63.
11. Pascolo S: Vaccination with messenger RNA (mRNA). Handb Exp Pharmacol 2008:221-35.
12. Van Craenenbroeck, Amaryllis H, Smits, Evelien L J, Anguille S, Van de Velde, Ann, Stein B, Braeckman T, van Camp K, Nijs G, Ieven M, Goossens H, Berneman ZN, Van Tendeloo, Viggo F I, Verpooten GA, van Damme P, Cools N: Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA-Transfected Dendritic Cells. Transplantation 2014.
13. Phua, Kyle K L, Nair SK, Leong KW: Messenger RNA (mRNA) nanoparticle tumour vaccination. Nanoscale 2014;6:7715-29.
14. Pollard C, Koker S de, Saelens X, Vanham G, Grooten J: Challenges and advances towards the rational design of mRNA vaccines. Trends Mol Med 2013;19:705-13.
15. Warren L, Manos PD, Ahfeldt T, Loh Y, Li H, Lau F, Ebina W, Mandal PK, Smith ZD, Meissner A, Daley GQ, Brack AS, Collins JJ, Cowan C, Schlaeger TM, Rossi DJ: Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell 2010;7:618-30.
16. Yakubov E, Rechavi G, Rozenblatt S, Givol D: Reprogramming of human fibroblasts to pluripotent stem cells using mRNA of four transcription factors. Biochem. Biophys. Res. Commun. 2010;394:189-93.
17. Kormann, Michael S D, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, Griese M, Bittmann I, Handgretinger R, Hartl D, Rosenecker J, Rudolph C: Expression of therapeutic proteins after delivery of chemically modified mRNA in mice. Nat. Biotechnol. 2011;29:154-7.
18. Kariko K, Muramatsu H, Keller JM, Weissman D: Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin. Mol. Ther 2012;20:948-53.
19. Quabius ES, Krupp G: Synthetic mRNAs for manipulating cellular phenotypes: an overview. N Biotechnol 2014.
20. Kariko K, Muramatsu H, Welsh FA, Ludwig J, Kato H, Akira S, Weissman D: Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol. Ther. 2008;16:1833-40.
21. Kariko K, Muramatsu H, Ludwig J, Weissman D: Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA. Nucleic Acids Res. 2011;39:el42.
22. Kariko K, Buckstein M, Ni H, Weissman D: Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity 2005;23:165-75.
23. Davis DR: Stabilization of RNA stacking by pseudouridine. Nucleic Acids Res. 1995:5020-6.
24. Nallagatla SR, Bevilacqua PC: Nucleoside modifications modulate activation of the protein kinase PKR in an RNA structure-specific manner. RNA 2008;14:1201-13.
25. Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann K, Schlee M, Endres S, Hartmann G: 5-Triphosphate RNA is the ligand for RIG-I. Science 2006;314:994-7.
26. Grassel S, Ahmed N: Influence of cellular microenvironmentand paracrine signals on chondrogenic differentiation. Front. Biosci. 2007;12:4946-56.
27. Eggenhofer E, Luk F, Dahlke MH, Hoogduijn MJ: The life and fate of mesenchymal stem cells. Front Immunol 2014;5:148.
28. Chou S, Lin S, Kuo W, Pai P, Lin J, Lai C, Kuo C, Lin K, Tsai F, Huang C: Mesenchymal stem cell insights: prospects in cardiovascular therapy. Cell Transplant 2014;23:513-29.
29. Kim N, Cho S: Clinical applications of mesenchymal stem cells. Korean J. Intern. Med. 2013;28:387-402.
30. Chen S, Fang W, Ye F, Liu Y, Qian J, Shan S, Zhang J, Chunhua RZ, Liao L, Lin S, Sun J: Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. The American journal of cardiology 2004;94:92-5.
31. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, Gerstenblith G, DeMaria AN, Denktas AE, Gammon RS, Hermiller JB, Reisman MA, Schaer GL, Sherman W: A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. Journal of the American College of Cardiology 2009;54:2277-86.
32. Mazhari R, Hare JM: Mechanisms of action of mesenchymal stem cells in cardiac repair: potential influences on the cardiac stem cell niche. Nature clinical practice. Cardiovascular medicine 2007;4 Suppl l:S21-6.
33. Gaebel R, Furlani D, Sorg H, Polchow B, Frank J, Bieback K, Wang W, Klopsch C, Ong L, Li W, Ma N, Steinhoff G: Cell origin of human mesenchymal stem cells determines a different healing performance in cardiac regeneration. PLoS ONE 2011;6:el5652.
34. David R, Brenner C, Stieber J, Schwarz F, Brunner S, Vollmer M, Mentele E, Miiller-Hocker J, Kitajima S, Lickert H, Rupp R, Franz W: MesPl drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. Nat. Cell Biol. 2008;10:338-45.
35. Davis RL, Weintraub H, Lassar AB: Expression of a Single Transfected cDNA Converts Fibroblasts to Myoblasts. Cell Press 1987;51:987-1000.
36. Symons JA, Alcami A, Smith GL: Vaccinia virus encodes a soluble type I interferon receptor of novel structure and broad species specificity. Cell 1995;81:551-60.